High serum levels of TNF-α and IL-6 predict the clinical outcome of treatment with human recombinant erythropoietin in anaemic cancer patients

Pavese, Ida; Satta, F.; Todi, F.; Palma, Mario Di; Piergrossi, P.; Migliore, Alberto; Piselli, Pierluca; Borghesi, R; Mancino, Giorgio; Brunetti, Ercole; Alimonti, Andrea

doi:10.1093/annonc/mdp568

Cited by 16 publications

(18 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Peak circulating levels (mean ± SEM) of IL‐6 or TNF‐α in response to fever or various moderate‐to‐severe inflammatory states . The IL‐6 and TNF‐α concentrations in cancer patients and in healthy subjects were obtained by compiling data from multiple references and calculating pooled standard deviations taking into account the different number of subjects, n , between trials.…”

Section: Markers Of Decreased Drug Clearance (Ie Acute Phase Reactmentioning

confidence: 99%

Understanding Disease–Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window

Coutant

Kulanthaivel

Turner

et al. 2015

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

The human inflammatory response can result in the alteration of drug clearance through effects on metabolizing enzymes or transporters. In this article we briefly review the theory of how cancer can lead to indirect changes in drug metabolism, review acute phase proteins and cytokines as markers of changes in cytochrome P450 (CYP) activity in cancer patients, and provide clinical case examples of how the inflammation in advanced cancer patients can lead to altered CYP-mediated drug clearance.

show abstract

Section: Markers Of Decreased Drug Clearance (Ie Acute Phase Reactmentioning

confidence: 99%

Understanding Disease–Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window

Coutant

Kulanthaivel

Turner

et al. 2015

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

show abstract

“…This decrease in the levels of the proinflammatory cytokines, particularly IL-6, may explain the decreases in hepcidin levels observed in EPO-treated subjects. Pavese et al [44] demonstrated that, in ESA-hyporesponsive cancer patients, high baseline serum levels of TNF-α and IL-6 were significantly correlated with a negative response to ESA. This may be attributed to the fact that profound and persistent inflammation, which may not be overcome by ESA administration, may decrease hepcidin levels and account for the reduced response to ESA treatment.…”

Section: Causal Role Of Hepcidin In Anemia Of Inflammation and Effectmentioning

confidence: 99%

Renal Anemia of Inflammation: The Name Is Self-Explanatory

et al. 2011

View full text Add to dashboard Cite

Background: Anemia is inevitable as chronic kidney disease (CKD) advances. With the advent of erythropoietin-stimulating agents (ESAs), considerable improvement has been achieved in the management of anemia. However, some patients show a reduced response to ESAs. Methods: Many factors affect the response to ESA treatment. CKD is now considered as an inflammatory disorder and this understanding led to the recognition of the central role of inflammation in ESA resistance. Inflammation is related to untoward outcomes, including atherosclerosis and anemia, in the CKD population. Furthermore, recognition of deleterious effects of proinflammatory markers at different levels of erythropoiesis led to a change in the name of ‘anemia of chronic disease’ to anemia of inflammation. Results: The discovery of hepcidin as the major controller of iron metabolism in anemia of inflammation answered many questions regarding the interaction of erythropoietin, iron and bone marrow. Hepcidin production in the liver is driven by three major factors: inflammation, iron overload and anemia/hypoxia. Hepcidin levels are increased in patients with CKD due to the interaction of many factors; a comprehensive understanding of these pathways is thus critical in the effort to alleviate anemia of inflammation and ESA resistance. Conclusion: In this review, we discussed the epidemiology, determinants and consequences of anemia of inflammation in CKD patients with special emphasis on the central role of hepcidin along with molecular pathways driving its production.

show abstract

“…Also, a fine Th1/Th2 immunity imbalance affects the IL-10/IL-12 regulatory circuit [14, 53, 54] and leads to over expression of IL-12 and TNF- α cytokines in patients with chronic fatigue. An increase of circulating TNF- α levels has been associated with significant fatigue in cholestatic patients with cancer [55]. Finally, work on animal models of chronic fatigue syndrome has also underlined the important pathogenic role of TRAF1-related cytokines, such as TNF α [32, 34].…”

Section: Discussionmentioning

confidence: 99%

TRAF1-C5Affects Quality of Life in Patients with Primary Biliary Cirrhosis

Raszeja‐Wyszomirska

Kempińska-Podhorodecka

Smyk

et al. 2013

Clinical and Developmental Immunology

View full text Add to dashboard Cite

Background. Previous studies reported associations between specific alleles of non-HLA immunoregulatory genes and higher fatigue scores in patients with primary biliary cirrhosis (PBC). Aim. To study the relationship between variables of health-related quality of life (HRQoL) and single nucleotide polymorphisms of TRAF1-C5, a member of the tumor necrosis factor receptor family. Patients and Methods. TRAF1-C5 gene polymorphisms, rs2900180 and rs3761847, were analysed in 120 Caucasian PBCs. The HRQoL was assessed with SF-36, PBC-40, and PBC-27 questionnaires. Results. We found a negative association between TT genotype of rs2900180 and SF-36's domains vitality (P < 0.05), mental health (P < 0.05), and mental component summary score (P < 0.05). GG homozygotes of rs3761847 had lower vitality (P < 0.05), mental health (P < 0.05), mental component summary score (P < 0.05) and impairment of social functioning (P < 0.01). Allelic analysis has shown that T allele of rs2900180 and G allele of rs3761847 related to SF-36's vitality (P < 0.05 and P < 0.01), social functioning (P < 0.05 and P < 0.05), mental health (P < 0.01 and P < 0.05), and mental component summary score (P < 0.01 and P < 0.05), respectively. Genotyping and allelic analysis did not reveal correlation with PBC-40 and PBC-27 domains. Conclusion. The association between rs2900180 and rs3761847 polymorphisms and HRQoL variables indicates that TRAF1 is involved in the induction of impaired QoL in PBC.

show abstract

High serum levels of TNF-α and IL-6 predict the clinical outcome of treatment with human recombinant erythropoietin in anaemic cancer patients

Cited by 16 publications

References 25 publications

Understanding Disease–Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window

Understanding Disease–Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window

Renal Anemia of Inflammation: The Name Is Self-Explanatory

TRAF1-C5Affects Quality of Life in Patients with Primary Biliary Cirrhosis

Contact Info

Product

Resources

About